Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 2/20 | 0.58 |
| ▸ | CYP11B2 | P19099 | 10/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 9/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6469473 | 0.80 | AR (0.66) | ARCYP11B2CYP11B1CYP19A1SQOR | |
| SCHEMBL6890107 | 0.76 | AR (0.58) | ARCYP11B2CYP11B1CYP19A1CYP3A4 | |
| SCHEMBL6884093 | 0.74 | AR (0.58) | ARCYP11B2CYP11B1CYP19A1CYP3A4 | |
| SCHEMBL6465272 | 0.73 | AR (1.00) | ARCYP11B2CYP11B1CYP19A1CYP3A4 | |
| SCHEMBL6464828 | 0.72 | AR (0.77) | ARCYP11B2CYP11B1CYP19A1CYP3A4 | |
| SCHEMBL6464840 | 0.71 | AR (0.78) | ARCYP11B2CYP11B1 | |
| SCHEMBL6468334 | 0.71 | AR (0.54) | ARCYP11B2CYP11B1 | |
| SCHEMBL6464186 | 0.69 | AR (0.81) | ARCYP11B2CYP11B1MAPK1CYP3A4 | |
| SCHEMBL6466418 | 0.68 | AR (0.80) | ARCYP11B2CYP11B1CYP19A1CYP3A4 | |
| SCHEMBL6465363 | 0.68 | AR (0.76) | ARCYP11B2CYP11B1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050101657-A1 | Pyrrole derivatives for preventing or treating cancer sensitive to hormones; administered with luteininzing hormone releasing hormone derivative | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101657-A1 | Pyrrole derivatives for preventing or treating cancer sensitive to hormones; administered with luteininzing hormone releasing hormone derivative | SHBG, PRLHR, FSHR | AR 6/4885CYP11B2 151/4885CYP11B1 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.